All products for:ImmunoassayRapid Tests bioNexiaMicrobiologyEmergency and Critical CareInfectious DiseasesRespiratory Tract Infections
  • BIONEXIA® Influenza A+B

BIONEXIA® Influenza A+B

Rapid detection and differentiation of flu viruses

BIONEXIA® Influenza A+B is a rapid test for the detection of Influenza A and B viruses in human nasopharyngeal specimens.

  • Convenient cassette format
  • Reliable result at 10 minutes with minimum training required
  • Safe and efficient sample collection1,2
  • All-in-one kit
Add to my selection

Do you need more information

Contact us

Influenza (commonly known as flu) is a highly contagious acute infection of the respiratory tract. Types A and B are the most common types of human influenza virus. They can circulate simultaneously, but usually one type is dominant during a seasonal epidemic. Although a flu infection is not normally severe, certain populations are at higher risk of developing complications.

Our BIONEXIA® Influenza A+B test is able to detect and differentiate the influenza B and influenza A viruses, including H1N1, H5N1, H3N2.... Rapid, accurate diagnosis
means reducing the risk of transmission and outbreak, preventing inappropriate antibiotic use and ensuring early prescription of antiviral medication for high-risk patients.
 

Safe and efficient sample collection

  • Flexible flocked swab for safe nasopharyngeal sample collection
  • In line with the WHO recommendations3
     

A convenient assay for rapid results

BIONEXIA® Influenza A+B safe cassette format

  • Detection and type differentiation of Influenza A and B in a single test
  • All material needed to perform the test included in the kit (with positive control)
  • Easy-to-use device
  • Quick User Guide printed on the box
  • Safe cassette format: no risk of contact with the biological material
  • Results available in just 10 minutes
  • Easy interpretation of results
     

INTERPRETATION

Positive results are indicated by 2 or 3 distinct colored lines depending on the type of antibody present: red line for Influenza A and/or blue line for Influenza B. The green control line must always be present.
 

Who is at risk?

Populations at high risk of complications include:

  • young children (6 months / 5 years old),
  • the elderly (over 65),
  • pregnant women,
  • patients with chronic health conditions such as heart disease, diabetes or asthma,
  • people in nursing homes or long-term care facilities,
  • immunocompromized populations.

References:

  1. Robinson JL, et al. Use of Throat Swab or Saliva Specimens for Detection of Respiratory Viruses in Children. CID 2008; 46 : e61-e64.
  2. Daley P, et al. Comparison of Flocked and Rayon Swabs for Collection of Respiratory Epithelial Cells from Uninfected Volunteers and Symptomatic Patients. J Clin Microbiol. 2006; 44 (6): 2265-2267.
  3. WHO recommendations on the use of rapid testing for influenza diagnosis. July 2005
  4. Picard C, et al. Comparative Evaluation Of BIONEXIA® Influenza A+B To QuickVue® Influenza A+B Test For The Detection Of Influenza In Pediatric Samples. Poster presented at ESPID congress May 28-June1, 2013. Milan, Italy.
  5. Briand H, et Al. Performance Evaluation of BIONEXIA® Influenza A+B, Rapid diagnosis test for the qualitativedetection of Influenza type A and type B antigens. Poster presented at RICAI congress Dec 1-2, 2011 (469)
  6. Bonner AB, et al. Pediatrics 2003;112:363-367

 

 

BIONEXIA® Influenza A+B
Reference 410 918
Content of the kit - 10 test cassettes in individually sealed pouches
- 10 sterile flocked swabs
- 10 extraction tubes with dropper caps
- 1 buffer bottle
- 1 positive control swab
- 1 reagent holder
- 1 quick user guide printed on the box
- 1 package insert
Sample type Human nasopharyngeal samples (swabs, aspirates, washes)
Time to result 10 minutes
Sample volume 3 drops of sample extract
Storage temperature 2 – 30°C
Shelf life 20 months from date of manufacturing

 

Kits are for professional use in laboratories.

Consult your local bioMérieux representative for product availability in your country.

Related Publications

  • Briand H, et al. Performance Evaluation of BIONEXIA® Influenza A+B, Rapid diagnosis test for the qualitative detection of Influenza type A and type B antigens. Poster presented at RICAI congress Dec 1-2, 2011 (469)
  • Picard C, et al. Comparative Evaluation Of BIONEXIA® Influenza A+B To QuickVue® Influenza A+B Test For The Detection Of Influenza In Pediatric Samples. Poster presented at ESPID congress May 28-June1, 2013. Milan, Italy.
     

Guidelines

WHO recommendations on the use of rapid testing for influenza diagnosis. July 2005
 

Useful Links

WHO (World Health Organization)

CDC (Centers for Disease Control and Prevention)

ECDC ( European Centre for Disease Prevention and Control)

 

 

 

Diagnostics is power